TenQ

The Oscar Health story

Oscar Health is a technology-driven individual health insurer whose central question is whether disciplined pricing can sustain profitable membership growth as medical costs and ACA enrollment rules change.

Oscar Health stock reportTenQ Score 17/36 · every chart and check from its filings
  • $31.89share price, last close
  • $9.8Bmarket value
  • 17/36TenQ Score checks passed

The story in brief

  • Individual coverage leads. After exiting small group plans and the Cigna+Oscar partnership, Oscar reached 2,963,002 effectuated members as of June 30, 2026, versus 2,027,148 a year earlier.
  • Reserves helped profitability. In the quarter to June 2026, the medical loss ratio improved to 79.2% from 91.1%, reflecting disciplined pricing and $164 million of favorable prior period reserve development.
  • Cash needs context. Oscar's $4.4 billion of free cash flow over the last twelve months is not an earnings measure for an insurer, so TenQ does not infer growth expectations from it.

What drives the business

  • Oscar focuses on individual ACA health plans, expanding coverage from 18 states for the 2025 policy year to 20 states for 2026, after the Cigna+Oscar Small Group arrangement ended on December 31, 2024.
  • Health insurance premiums generate the vast majority of revenue, with 93% of premiums earned directly from the Centers for Medicare & Medicaid Services through advanced premium tax credits and 7% from members in 2025.
  • Its employer expansion strategy centers on Individual Coverage Health Reimbursement Arrangements, which let employees use employer contributions for individual coverage, supported by the 2025 acquisitions of Lucie, IHC Specialty Benefits, and Healthinsurance.org.
  • Beyond insurance, Oscar offers its technology through +Oscar, whose Campaign Builder engagement platform served nearly 0.6 million client lives as of December 31, 2025.
  • Higher membership and rate increases lifted revenue to approximately $4.9 billion in the quarter to June 2026 from $2.9 billion a year earlier, while improved underwriting and favorable reserve development produced $388.6 million in earnings from operations.

What the price assumes

The growth embedded in Oscar's $33.11 share price is not measured because an insurer's free cash flow does not measure what it earns, so TenQ does not run a reverse DCF.

The price represents 15.8x earnings, and the 6.3% earnings yield exceeds the 5.3% Treasury benchmark used by TenQ.

Revenue grew 42.8% over the last twelve months against a 43.5% annual pace over the last three years, but Oscar fails TenQ's price versus growth check because it lacks positive three-year earnings growth.

What could change the story

  • The $164 million benefit from favorable prior period reserve development means the medical loss ratio improvement cannot be attributed entirely to pricing and ongoing claims performance.
  • Medical costs generally shift toward Oscar in the second half of the policy year as members meet deductibles, while changes in market health risk and risk adjustment estimates can alter net premiums.
  • Dependence on CMS premium payments exposes enrollment and revenue to changes in premium tax credits, eligibility verification, and other ACA rules.
  • Despite the expense improvement in the quarter to June 2026, TenQ's broader expense comparison is 95.9% of revenue against an 83.1% sector benchmark, leaving Oscar below the check's efficiency bar.
  • The share count rose 23.5% over three years, and Oscar made no share repurchases against $75 million of stock-based pay over the last twelve months.

What to watch next

  • Oscar's August 2026 outlook raised full year 2026 earnings from operations to $500 million to $700 million, with a medical loss ratio of 81.5% to 82.5% and an SG&A expense ratio of 15.6% to 16.1%.
  • The September 16, 2026 announcement indicated further improvements to full year 2026 guidance, making the next earnings release an important point for reconciling the outlook with subsequent performance.
  • Membership retention, rate increases, and risk adjustment accruals will help explain revenue performance against the August 2026 full year outlook of $18.7 billion to $19.0 billion.
  • The next release's medical loss ratio, reserve revisions, and administrative expense ratio will distinguish ongoing operating improvement from favorable adjustments to earlier estimates.

Sources

Back to the OSCR report